BOSTON – With hepatitis C on the decline, non-alcoholic steatohepatitis is becoming the focus of liver disease R&D. While Intercept Pharmaceuticals Inc. and Genfit SA have the early lead in drug development, recent deal-making by Allergan PLC and Bristol-Myers Squibb Co., as well as a reshuffled strategy at Gilead Sciences Inc., appear to have the competition in flux.
Combination Strategies A Common Thread In NASH R&D
Intercept continues to lead the non-alcoholic steatohepatitis race, but some analysts think Gilead is making up ground; data presented at AASLD shows those two, along with Allergan/Tobira and Bristol, are jockeying to produce combination regimens for the unmet medical need.